Sirolimus versus cyclosporine A in patients with primary acquired pure red cell aplasia: a prospective cohort study
Open Access
- 10 May 2023
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 13 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Formation and optimization of three-dimensional organoids generated from urine-derived stem cells for renal function in vitroStem Cell Research & Therapy, 2020
- Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimusAnnals of Hematology, 2018
- Rapamycin is highly effective in murine models of immune-mediated bone marrow failureHaematologica, 2017
- Pure red cell aplasiaHematology-American Society Hematology Education Program, 2016
- Pure red cell aplasiaBlood, 2016
- Rapamycin passes the torch: a new generation of mTOR inhibitorsNature Reviews Drug Discovery, 2011
- Acquired pure red cell aplasia: updated review of treatmentBritish Journal of Haematology, 2008
- Sirolimus: its discovery, biological properties, and mechanism of actionTransplantation Proceedings, 2003
- Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes.1998
- Role of the Kidney in ErythropoiesisNature, 1957